1)Bartlett JG, et al:Role of Clostridium difficile in antibiotic-associated pseudomembranous colitis. Gastroenterology 75:778-782, 1978
2)McDonald LC, et al:Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children:2017 Update by the Infectious Diseases Society of America(IDSA)and Society for Healthcare Epidemiology of America(SHEA). Clin Infect Dis Off Publ Infect Dis Soc Am 66:e1-48, 2018
3)Venugopal AA, Johnson S:Fidaxomicin:A novel macrocyclic antibiotic approved for treatment of Clostridium difficile infection. Clin Infect Dis 54:568-574, 2012
Infection. N Engl J Med 364:422-431, 2011
5)Cornely OA, et al:Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA:a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis 12:281-289, 2012
6)Cornely OA, et al:Treatment of first recurrence of Clostridium difficile infection:Fidaxomicin versus vancomycin. Clin Infect Dis 55(Suppl 2):S154-161, 2012
7)Cornely OA, et al:Resolution of Clostridium difficile-associated diarrhea in patients with cancer treated with fidaxomicin or vancomycin. J Clin Oncol 31:2493-2499, 2013
8)Mullane KM, et al:A Randomized, Placebo-controlled Trial of Fidaxomicin for Prophylaxis of Clostridium difficile-associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation. Clin Infect Dis 68:196-203, 2019
9)Weiss K, et al:Safety Analysis of Fidaxomicin in Comparison with Oral Vancomycin for Clostridium difficile Infections. Clin Infect Dis 55(Suppl 2):S110-115, 2012
10)Abughanimeh OKM, et al:The economic effectiveness of fidaxomicin over vancomycin in treating clostridium difficile infection in cancer patients:A systematic review. J Clin Oncol 36(15_suppl):e18923-e18923, 2018